IMMUNOSUPPRESSION AND PLASMAPHERESIS IN GOODPASTURE'S SYNDROME

Goodpasture 综合征中的免疫抑制和血浆去除术

• 批准号: 3964768
• 负责人: J E BALOW
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3964768
• 关键词: Goodpasture's syndrome; autoantibody; autoimmune disorder; drug adverse effect; glomerulonephritis; human subject; human therapy evaluation; immunopathology chemotherapy; immunosuppression; immunosuppressive; kidney disorder; metabolism disorder; plasmapheresis

Goodpasture's Syndrome is usually characterized by rapidly progressive glomerulonephritis due to autoantibodies against glomerular basement membrane (anti-GBM). This study will examine whether plasmapheresis significantly improves the results of standard immunosuppressive drug treatment of this disease. Patients will be randomly allocated to drug treatment alone or drugs plus plasmapheresis until anti-GBM levels are undetectable. Comparison will be made of the numbers of favorable outcomes and complication rates of these therapies at the end of 6 months of study. Analysis of the balance of efficacy, complications and expense of plasmapheresis in treatment of Goodpasture's syndrome will be facilitated by the results of this study.

Goodpasture综合征通常以快速进展为特征